<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Stereotaxis, Inc. — News on 6ix</title>
<link>https://6ix.com/company/stereotaxis-inc</link>
<description>Latest news and press releases for Stereotaxis, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 11:58:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/stereotaxis-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7885251cc36e475343f47.webp</url>
<title>Stereotaxis, Inc.</title>
<link>https://6ix.com/company/stereotaxis-inc</link>
</image>
<item>
<title>Stereotaxis Announces First MAGiC Procedures in the United States</title>
<link>https://6ix.com/company/stereotaxis-inc/news/stereotaxis-announces-first-magic-procedures-in-the-united-states-5</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/stereotaxis-announces-first-magic-procedures-in-the-united-states-5</guid>
<pubDate>Wed, 22 Apr 2026 11:58:00 GMT</pubDate>
<description>ST. LOUIS, April 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the US have been successfully treated using MAGiC™. MAGiC, Stereotaxis’ proprietary robotically-navigated magnetic interventional cardiac ablation catheter, recently received Food & Drug Administration PMA approval. It is the first ablation catheter specifically approved to treat arrhythmia</description>
</item>
<item>
<title>Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026</title>
<link>https://6ix.com/company/stereotaxis-inc/news/stereotaxis-to-report-first-quarter-2026-financial-results-on-may-12-2026</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/stereotaxis-to-report-first-quarter-2026-financial-results-on-may-12-2026</guid>
<pubDate>Tue, 21 Apr 2026 13:01:00 GMT</pubDate>
<description>ST. LOUIS, April 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 first quarter on Tuesday, May 12, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments. What: Stereotaxis first quarter 2026 fi</description>
</item>
<item>
<title>Stereotaxis Announces Definitive Agreement to Acquire Robocath</title>
<link>https://6ix.com/company/stereotaxis-inc/news/stereotaxis-announces-definitive-agreement-to-acquire-robocath</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/stereotaxis-announces-definitive-agreement-to-acquire-robocath</guid>
<pubDate>Wed, 15 Apr 2026 11:00:00 GMT</pubDate>
<description>ST. LOUIS and ROUEN, France, April 15, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a definitive agreement to acquire Robocath, a venture-backed innovator of robotic technologies for interventional cardiology and neurointerventions. This acquisition significantly strengthens Stereotaxis’ position as a leading platform for the full spectrum of endovascu</description>
</item>
<item>
<title>Stereotaxis Announces FDA Clearance and Launch of Synchrony System</title>
<link>https://6ix.com/company/stereotaxis-inc/news/stereotaxis-announces-fda-clearance-and-launch-of-synchrony-system</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/stereotaxis-announces-fda-clearance-and-launch-of-synchrony-system</guid>
<pubDate>Mon, 06 Apr 2026 12:06:00 GMT</pubDate>
<description>ST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration 510(k) clearance for the Synchrony™ system. Synchrony is designed to digitize and modernize the interventional cath lab. Synchrony’s slim and stunning 55” 4K ultra-high-definition display consolidates the viewing and control of all disparate systems in the l</description>
</item>
<item>
<title>Stereotaxis Reports 2025 Full Year Financial Results</title>
<link>https://6ix.com/company/stereotaxis-inc/news/stereotaxis-reports-2025-full-year-financial-results-2</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/stereotaxis-reports-2025-full-year-financial-results-2</guid>
<pubDate>Mon, 09 Mar 2026 20:01:00 GMT</pubDate>
<description>ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025. “The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad pipeline of innovations, and revenue growth of over 20%. I’m proud of what our team has accomplished and excited for the yea</description>
</item>
<item>
<title>Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026</title>
<link>https://6ix.com/company/stereotaxis-inc/news/stereotaxis-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-9-2026</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/stereotaxis-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-9-2026</guid>
<pubDate>Thu, 12 Feb 2026 14:00:00 GMT</pubDate>
<description>ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 fourth quarter and full year on Monday, March 9, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments. What:Stereotaxis fourth qu</description>
</item>
<item>
<title>Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program</title>
<link>https://6ix.com/company/stereotaxis-inc/news/klinikum-furth-establishes-leading-robotic-heart-arrhythmia-program</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/klinikum-furth-establishes-leading-robotic-heart-arrhythmia-program</guid>
<pubDate>Mon, 09 Feb 2026 13:06:00 GMT</pubDate>
<description>ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of a new robotic electrophysiology program at Klinikum Fürth in Fürth, Germany. Klinikum Fürth is the first hospital in Germany to establish a leading heart rhythm program that incorporates the Genesis Robotic Magnetic Navigation System, advanced robotic technology that establishes a new standard of ca</description>
</item>
<item>
<title>Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter</title>
<link>https://6ix.com/company/stereotaxis-inc/news/stereotaxis-receives-fda-approval-for-magic-ablation-catheter</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/stereotaxis-receives-fda-approval-for-magic-ablation-catheter</guid>
<pubDate>Tue, 06 Jan 2026 13:01:00 GMT</pubDate>
<description>ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S. Food and Drug Administration (FDA) approval for the MAGiC™ Magnetic Interventional Ablation Catheter. “FDA approval of MAGiC is a significant milestone for Stereotaxis and the community of physicians pioneering robotics in electrophysiology. It ensures the benefits of Robotic Magnetic Navigation</description>
</item>
<item>
<title>Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/stereotaxis-inc/news/stereotaxis-to-participate-in-piper-sandler-37th-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/stereotaxis-to-participate-in-piper-sandler-37th-annual-healthcare-conference</guid>
<pubDate>Mon, 24 Nov 2025 13:58:00 GMT</pubDate>
<description>ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company will participate in the Piper Sandler 37th Annual Healthcare Conference. David Fischel, Stereotaxis Chairman and CEO, is scheduled to participate in a fireside discussion on Wednesday, December 3rd, 2025, at 9:00 am Eastern Standard Time and will be available that same day for one-on-one meetings</description>
</item>
<item>
<title>Stereotaxis Reports 2025 Third Quarter Financial Results</title>
<link>https://6ix.com/company/stereotaxis-inc/news/stereotaxis-reports-2025-third-quarter-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/stereotaxis-reports-2025-third-quarter-financial-results</guid>
<pubDate>Tue, 11 Nov 2025 21:01:00 GMT</pubDate>
<description>ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2025. “We continue to focus on driving commercial progress while advancing a robust portfolio of technologies through regulatory and development milestones,” said David Fischel, Chairman and CEO. “This is an exciting milestone-rich period in which we are</description>
</item>
<item>
<title>GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance</title>
<link>https://6ix.com/company/stereotaxis-inc/news/genesisx-robotic-magnetic-navigation-system-receives-us-fda-clearance</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/genesisx-robotic-magnetic-navigation-system-receives-us-fda-clearance</guid>
<pubDate>Mon, 10 Nov 2025 21:05:00 GMT</pubDate>
<description>ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received U.S. Food and Drug Administration 510(k) clearance for its latest generation robotic system, GenesisX™. GenesisX is the latest advance in endovascular surgical robotics, building upon the established benefits of Robotic Magnetic Navigation while significantly enhancing the accessibility of the te</description>
</item>
<item>
<title>Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025</title>
<link>https://6ix.com/company/stereotaxis-inc/news/stereotaxis-to-report-third-quarter-2025-financial-results-on-november-11-2025</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/stereotaxis-to-report-third-quarter-2025-financial-results-on-november-11-2025</guid>
<pubDate>Tue, 21 Oct 2025 13:00:00 GMT</pubDate>
<description>ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 third quarter on Tuesday, November 11, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments. What:Stereotaxis third quarter 2025</description>
</item>
<item>
<title>Stereotaxis Announces EU Launch and 510(k) Submission for Synchrony System to Modernize Interventional Cath Labs</title>
<link>https://6ix.com/company/stereotaxis-inc/news/stereotaxis-announces-eu-launch-and-510k-submission-for-synchrony-system-to-modernize-interventional-cath-labs</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/stereotaxis-announces-eu-launch-and-510k-submission-for-synchrony-system-to-modernize-interventional-cath-labs</guid>
<pubDate>Wed, 15 Oct 2025 11:32:00 GMT</pubDate>
<description>ST. LOUIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE Mark in Europe and submitted a 510(k) application to the FDA in the US for the Synchrony™ system. Synchrony is designed to digitize and modernize the interventional cath lab. Synchrony’s slim and stunning 55” 4K ultra-high-definition display consolidates the viewing and control of all disparate sys</description>
</item>
<item>
<title>Stereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac Arrhythmias</title>
<link>https://6ix.com/company/stereotaxis-inc/news/stereotaxis-and-cardiofocus-collaborate-to-advance-robotic-pulsed-field-ablation-for-cardiac-arrhythmias</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/stereotaxis-and-cardiofocus-collaborate-to-advance-robotic-pulsed-field-ablation-for-cardiac-arrhythmias</guid>
<pubDate>Mon, 13 Oct 2025 11:34:00 GMT</pubDate>
<description>ST. LOUIS and MARLBOROUGH, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, and CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced they have entered into a Collaboration Agreement to advance robotic Pulsed Field Ablation (PFA) technology towards commercialization. The collaboration combines the proprietary</description>
</item>
<item>
<title>Erasmus Medical Center Advances Cardiovascular Care with Genesis Robotic System</title>
<link>https://6ix.com/company/stereotaxis-inc/news/erasmus-medical-center-advances-cardiovascular-care-with-genesis-robotic-system</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/erasmus-medical-center-advances-cardiovascular-care-with-genesis-robotic-system</guid>
<pubDate>Mon, 22 Sep 2025 11:56:00 GMT</pubDate>
<description>ST. LOUIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced successful first procedures by physicians at Erasmus University Medical Center in Rotterdam, The Netherlands, using the advanced Genesis Robotic Magnetic Navigation System. “We have long recognized the clinical benefits of robotics, and are delighted to be the first in The Netherlands to make the Genesis robotic</description>
</item>
<item>
<title>First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter</title>
<link>https://6ix.com/company/stereotaxis-inc/news/first-us-commercial-robotic-hd-mapping-procedures-successfully-completed-with-magic-sweep-catheter</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/first-us-commercial-robotic-hd-mapping-procedures-successfully-completed-with-magic-sweep-catheter</guid>
<pubDate>Tue, 02 Sep 2025 12:08:00 GMT</pubDate>
<description>ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the successful completion of the world’s first procedures using MAGiC Sweep™, the first and only robotically-navigated high-density electrophysiology (EP) mapping catheter. The procedures were performed by Dr. Raffaele Corbisiero and Dr. Pedram Kazemian at Deborah Heart and Lung Center in Browns Mills, New Jerse</description>
</item>
<item>
<title>Stereotaxis to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/stereotaxis-inc/news/stereotaxis-to-present-at-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/stereotaxis-to-present-at-upcoming-investor-conferences</guid>
<pubDate>Tue, 02 Sep 2025 11:51:00 GMT</pubDate>
<description>ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will present at two investor conferences in New York City in September. H.C. Wainwright 27th Annual Global Investment ConferenceMr. Fischel will present an overview of Stereotaxis business on Wednesday, September 10th, 2025, at 8:00 am EDT and will be available that same day</description>
</item>
<item>
<title>Stereotaxis Technology to be Featured at Heart Rhythm Society’s HRX 2025</title>
<link>https://6ix.com/company/stereotaxis-inc/news/stereotaxis-technology-to-be-featured-at-heart-rhythm-societys-hrx-2025</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/stereotaxis-technology-to-be-featured-at-heart-rhythm-societys-hrx-2025</guid>
<pubDate>Thu, 28 Aug 2025 11:47:00 GMT</pubDate>
<description>ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health conference taking place September 4-6, 2025, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society, is focused on exploring digital technologies that advance the frontiers of cardiovascular medicine. Stereotaxis CEO, Da</description>
</item>
<item>
<title>Stereotaxis Reports 2025 Second Quarter Financial Results</title>
<link>https://6ix.com/company/stereotaxis-inc/news/stereotaxis-reports-2025-second-quarter-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/stereotaxis-reports-2025-second-quarter-financial-results</guid>
<pubDate>Thu, 07 Aug 2025 20:01:00 GMT</pubDate>
<description>ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025. “We are pleased with our commercial results in the quarter. Sequential and year-over-year growth in both recurring and system revenue reflects the early positive impact of our innovations on commercial adoption,” said David Fischel, Chairman and CEO. “T</description>
</item>
<item>
<title>Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter</title>
<link>https://6ix.com/company/stereotaxis-inc/news/stereotaxis-receives-us-fda-clearance-for-magic-sweep-catheter</link>
<guid isPermaLink="true">https://6ix.com/company/stereotaxis-inc/news/stereotaxis-receives-us-fda-clearance-for-magic-sweep-catheter</guid>
<pubDate>Mon, 28 Jul 2025 11:48:00 GMT</pubDate>
<description>ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its groundbreaking MAGiC Sweep™ catheter. MAGiC Sweep is the world’s first robotically navigated high-density electrophysiology (EP) mapping catheter, representing a significant advancement in the technology available to diagnose an</description>
</item>
</channel>
</rss>